The Neuroleptic Malignant Syndrome;Das maligne neuroleptische Syndrom (MNS) - Eine systematische Übersicht

Fortschritte der Neurologie Psychiatrie

Volumn 83, Issue 7, 2015, Pages 373-380

  Nagel, M ^a   Freisberg, S ^b   Junghanns, K ^a   Moll, C K E ^c   Willenborg, B ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Psychiatrie Asklepios Klinik Nord Wandsbek   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

akinetic crisis; antipsychotics; catatonia; hyperthermia; neuroleptic malignant syndrome; neuroleptics

Indexed keywords

CREATINE KINASE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ARTICLE; AUTONOMIC NEUROPATHY; DIAPHORESIS; DRUG EXPOSURE; EARLY INTERVENTION; HUMAN; HYPERTHERMIA; MENTAL DETERIORATION; NEUROLEPTIC MALIGNANT SYNDROME; RIGIDITY; SYSTEMATIC REVIEW; DIFFERENTIAL DIAGNOSIS; META ANALYSIS; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; RISK FACTORS;

EID: 84937804219     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0035-1553246     Document Type: Article

References (75)

1. Ayd F. J. Jr. Fatal hyperpyrexia during chlorpromazine therapy. J Clin Exp Psychopathol: 1956; 17 189 192
2. Delay J., Pichot P., Lemperiere T. et al. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris): 1960; 118 01 145 152
3. Haddad P. M. Neuroleptic malignant syndrome. May be caused by other drugs. BMJ: 1994; 308 200
4. Ananth J., Parameswaran S., Gunatilake S. et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry: 2004; 65 464 470
5. Bottlender R., Jager M., Hofschuster E. et al. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry: 2002; 35 119 121
6. Trollor J. N., Chen X., Chitty K. et al. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry: 2012; 201 52 56
7. Assion H. J., Volz H. P. Malignes neuroleptisches Syndrom. 1. Aufl Stuttgart Thieme: 2004
8. American Psychiatric Association DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th. Aufl Arlington VA: American Psychiatric Association: 2013
9. Chang C. K., Harrison S., Lee W. et al. Ascertaining instances of neuroleptic malignant syndrome in a secondary mental healthcare electronic medical records database: the SLAM BRC Case Register. Ther Adv Psychopharmacol: 2012; 2 75 83
10. Haddad P. M., Mattey V. S. Hrsg Neurological complications of antipsycotic drugs. 3. Aufl Bethesda Wiley-Blackwell: 2011
11. Addonizio G., Susman V. L., Roth S. D. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry: 1987; 22 1004 1020
12. Caroff S. N., Mann S. C. Neuroleptic malignant syndrome. Med Clin North Am: 1993; 77 185 202
13. Levenson J. L. Neuroleptic malignant syndrome. Am J Psychiatry: 1985; 142 1137 1145
14. Strawn J. R., Keck P. E. Jr, Caroff S. N. Neuroleptic malignant syndrome. Am J Psychiatry: 2007; 164 870 876
15. Woodbury M. M., Woodbury M. A. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry: 1992; 31 1161 1164
16. Gurrera R. J., Caroff S. N., Cohen A. et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry: 2011; 72 1222 1228
17. Stubner S., Rustenbeck E., Grohmann R. et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry: 2004; 37 01 S54 S64
18. Nielsen R. E., Wallenstein Jensen S. O., Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry: 2012; 57 512 518
19. Shalev A., Hermesh H., Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry: 1989; 50 18 25
20. Nakamura M., Yasunaga H., Miyata H. et al. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry: 2012; 73 427 430
21. Caroff S. N., Hurford I., Lybrand J. et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin: 2011; 29 127 148, viii
22. Panagariya A., Sharma B., Singh R. et al. The neuroleptic malignant syndrome: a report of 14 cases from North India. Neurol India: 2007; 55 166 168
23. Tural U., Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci: 2010; 64 79 87
24. Caroff S. N. The neuroleptic malignant syndrome. J Clin Psychiatry: 1980; 41 79 83
25. Margetic B., Aukst-Margetic B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf: 2010; 19 429 435
26. Moscovich M., Novak F. T., Fernandes A. F. et al. Neuroleptic malignant syndrome. Arq Neuropsiquiatr: 2011; 69 751 755
27. Viejo L. F., Morales V., Punal P. et al. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand: 2003; 107 45 49
28. Su Y. P., Chang C. K., Hayes R. D. et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand: 2014; 130 52 60
29. Langan J., Martin D., Shajahan P. et al. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry: 2012; 12 214
30. Guze B. H., Baxter L. R. Jr. Current concepts. Neuroleptic malignant syndrome. N Engl J Med: 1985; 313 163 166
31. Mann S. C., Auriacombe M., Macfadden W. et al. Lethal catatonia: clinical aspects and therapeutic intervention. A review of the literature. Encephale: 2001; 27 213 216
32. Argyriou A. A., Drakoulogona O., Karanasios P. et al. Lithium-induced fatal neuroleptic malignant syndrome in a patient not being concomitantly treated with commonly offending agents. J Pain Symptom Manage: 2012; 44 e4 e6
33. Shalev A., Hermesh H., Munitz H. The role of external heat load in triggering the neuroleptic malignant syndrome. Am J Psychiatry: 1988; 145 110 111
34. Ziegenbein M., Kropp S., Hillemacher T. et al. Genetic predisposition to neuroleptic malignant syndrome in siblings. Ann Pharmacother: 2006; 40 574 575
35. Suzuki A., Kondo T., Otani K. et al. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry: 2001; 158 1714 1716
36. Carroll B. T., Lee J. W. Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry: 2004; 65 1722 1723
37. Assion H. J., Heinemann F., Laux G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci: 1998; 248 231 239
38. Toro-Chico P., Gil Navarro I., Perez Encinas M. Neuroleptic malignant syndrome in association with tricyclic antidepressants. Farm Hosp: 2006; 30 261 262
39. Gurrera R. J. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry: 1999; 156 169 180
40. Haddow A. M., Harris D., Wilson M. et al. Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin. BMJ: 2004; 329 1333 1335
41. Pelonero A. L., Levenson J. L., Pandurangi A. K. Neuroleptic malignant syndrome: a review. Psychiatr Serv: 1998; 49 1163 1172
42. O'Dwyer A. M., Sheppard N. P. The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. Psychol Med: 1993; 23 323 326
43. Calmeil L. F. Dictionnarie de medicine ou repertoire general des sciences. Medicales sous le rapport therorique et practique. In: 2nd ed Paris Bechet: 1832
44. Fink M., Shorter E., Taylor M. A. Catatonia is not schizophrenia: Kraepelin's error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophr Bull: 2010; 36 314 320
45. Mann S. C., Caroff S. N., Bleier H. R. et al. Lethal catatonia. Am J Psychiatry: 1986; 143 1374 1381
46. Koch M., Chandragiri S., Rizvi S. et al. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry: 2000; 41 73 75
47. Fink M., Taylor M. A. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry: 2006; 30 1182 1183; author reply 1184-1185
48. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry: 1996; 39 1 4
49. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry: 1996; 29 159 161
50. Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm: 2002; 109 1453 1467
51. Kipps C. M., Fung V. S., Grattan-Smith P. et al. Movement disorder emergencies. Mov Disord: 2005; 20 322 334
52. Sternbach H. The serotonin syndrome. Am J Psychiatry: 1991; 148 705 713
53. Onofrj M., Thomas A. Acute akinesia in Parkinson disease. Neurology: 2005; 64 1162 1169
54. Munhoz R. P., Moscovich M., Araujo P. D. et al. Movement disorders emergencies: a review. Arq Neuropsiquiatr: 2012; 70 453 461
55. Douglas A., Morris J. It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease. Age Ageing: 2006; 35 640 641
56. Keyser D. L., Rodnitzky R. L. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med: 1991; 151 794 796
57. Mizuno Y., Takubo H., Mizuta E. et al. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord: 2003; 9 01 S3 S9
58. Vincent A. Autoimmune encephalitis. J Neurol Neurosurg Psychiatry: 2014; 85 e3
59. Henderson V. W., Wooten G. F. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology: 1981; 31 132 137
60. Osman A. A., Khurasani M. H. Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis. Br J Psychiatry: 1994; 165 548 550
61. Gillman P. K. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord: 2010; 25 1780 1790
62. Kornhuber J., Weller M., Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect: 1993; 6 63 72
63. Nisijima K., Shioda K., Iwamura T. Neuroleptic malignant syndrome and serotonin syndrome. Prog Brain Res: 2007; 162 81 104
64. Kontaxakis V. P., Havaki-Kontaxaki B. J., Christodoulou N. G. et al. Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome? Ann Gen Hosp Psychiatry: 2003; 2 10
65. Rosebush P. I., Mazurek M. F. Serum iron and neuroleptic malignant syndrome. Lancet: 1991; 338 149 151
66. Anglin R. E., Rosebush P. I., Mazurek M. F. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CMAJ: 2010; 182 E834 E838
67. Rosebush P. I., Anglin R. E., Richards C. et al. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol: 2008; 28 459 461
68. Ferentinos P., Dikeos D. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry: 2012; 25 381 390
69. Velamoor V. R., Norman R. M., Caroff S. N. et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis: 1994; 182 168 173
70. Nisijima K., Shioda K. Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome. Neuropsychiatr Dis Treat: 2013; 9 853 859
71. Caroff S. N., Mann S. C. Hrsg. Neuroleptic malignant syndrome. 2. Aufl Washington D. C American Psychiatric Publishing: 2003; 1 44
72. Francis A., Chandragiri S., Rizvi S. et al. Is Lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectr: 2000; 5 54 57
73. Reulbach U., Dutsch C., Biermann T. et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care: 2007; 11 R4
74. Trollor J. N., Sachdev P. S. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry: 1999; 33 650 659
75. Ambulkar R. P., Patil V. P., Moiyadi A. V. Neuroleptic malignant syndrome: A diagnostic challenge. J Anaesthesiol Clin Pharmacol: 2012; 28 517 519